BackTable Tumor Board

BackTable Tumor Board is a multi-disciplinary podcast for healthcare professionals that play an active role in cancer care.

BackTable Tumor Board is a health podcast hosted by Unknown Host, with 83 episodes on record and a Required Pod Score of 80.

Unknown Host hosts BackTable Tumor Board, a health show with 83 episodes published.

Our AI reads these to draft pitches. Use them as grounding for a pitch that cites a real guest and a specific topic.

• 

  BackTable Tumor Board

  Ep. 83 Molecular-Driven Therapies in Colorectal Cancer with Dr. Ibrahim Sahin and Dr. Sandra Algaze

  Sep 29, 202645 min

  Which molecular alterations in colorectal cancer now change treatment and how quickly do you need the results to make the right call? On this episode of BackTable Tumor Board, Dr. Jun Gong interviews Dr. Ibrahim Sahin and Dr. Sandra Algaze about the latest advances in molecular-driven therapy across adjuvant and metastatic settings. They cover aspirin in PI3K-altered disease, the shift toward early next-generation sequencing, and the operational realities of systematic profiling at diagnosis. --- Get the BackTable apphttps://www.backtable.com/app --- Timestamps 00:00 - Introduction07:50 - BREAKWATER and First-Line BRAF Therapy13:00 - Biomarker Turnaround and Systematic Profiling17:58 - MSI-High Disease and Immunotherapy Trials21:54 - Anti-PD-1 vs Anti-PD-L1 in CRC25:17 - Doublet vs Single-Agent Immunotherapy27:41 - KRYSTAL-10 and KRAS G12C Inhibition33:34 - Anti-EGFR Sequencing and CR-SEQUENCE38:47 - New Targets and Emerging Therapies43:02 - Closing Remarks --- More about this episode The discussion moves from first-line BRAF and MSI-high options to anti-EGFR sequencing, ctDNA hyperselection, and the nuances of chemotherapy backbone choice. Drs. Sahin and Algaze review new trial data including BREAKWATER, KEYNOTE-177, CheckMate 8HW, KRYSTAL-10, and CR-SEQUENCE, highlight the promise and pitfalls of targeted strategies, and close with a look at emerging therapies and the multidisciplinary teamwork needed to match biology to treatment. --- Resources ALASCCA: Low-Dose Aspirin for PI3K-Altered Localized Colorectal Cancer (NEJM)https://www.nejm.org/doi/full/10.1056/NEJMoa2504650 BREAKWATER: Encorafenib, Cetuximab, and mFOLFOX6 in BRAF-Mutated Colorectal Cancer (NEJM)https://www.nejm.org/doi/full/10.1056/NEJMoa2501912 COMMIT (NRG-GI004 / SWOG-S1610): Atezolizumab Monotherapy vs mFOLFOX6/Bevacizumab/Atezolizumab in dMMR/MSI-H mCRChttps://clinicaltrials.gov/study/NCT02997228 CheckMate 8HW: Nivolumab Plus Ipilimumab Versus Nivolumab in MSI-High Metastatic Colorectal Cancer (The Lancet)https://pubmed.ncbi.nlm.nih.gov/39874977/ KRYSTAL-10: Adagrasib Plus Cetuximab Versus Chemotherapy in Previously Treated KRAS G12C-Mutated Colorectal Cancerhttps://clinicaltrials.gov/study/NCT04793958 CR-SEQUENCE: Anti-EGFR Versus Anti-VEGF Sequencing in RAS Wild-Type Left-Sided mCRC (ASCO 2026 Abstract)https://ascopubs.org/doi/10.1200/JCO.2026.44.16_suppl.3512 --- BackTable Tumor Board is the go-to multidisciplinary podcast for medical oncologists, surgical oncologists, and other healthcare professionals that play an active role in cancer care. Download the free BackTable app to get early access to new episodes, cases, and courses curated by physicians in your specialty. ► https://www.backtable.com/app

  ListenShow Notes
• 

  BackTable Tumor Board

  Ep. 82 Advances in Perioperative Colorectal Cancer Management with Dr. Ibrahim Sahin and Dr. Alexandra Gangi

  Sep 22, 202642 min

  How much of perioperative colorectal cancer management has changed in just one year, and what does it mean for patient care? On this episode of BackTable Tumor Board, Dr. Jun Gong is joined by Dr. Ibrahim Sahin and Dr. Alexandra Gangi to review the latest practice-changing data in colon and rectal cancer. They discuss observation versus maintenance immunotherapy in MSI-high disease, the CHALLENGE trial's surprising results on exercise and disease-free survival, and the evolving role of ctDNA and local therapies after liver metastasis resection. The conversation also covers adjuvant immunotherapy duration, comparing microwave ablation with SBRT, and how molecular residual disease (MRD) can guide post-resection decisions. They walk through a complex case of liver metastases, highlight the use of hepatic arterial infusion pumps, and discuss the future of transplant for unresectable disease. The discussion closes with practical advice on patient selection, multidisciplinary care, and the ongoing need for consensus as new therapies and biomarkers emerge. --- Get the BackTable apphttps://www.backtable.com/app --- Timestamps 00:00 - Introduction05:29 - Monotherapy, Doublet, and Treatment Duration10:35 - CHALLENGE Trial and Exercise After Surgery16:18 - Adjuvant Immunotherapy and Liver Metastases23:39 - ctDNA and Molecular Residual Disease29:44 - Case: Unresectable Liver Metastases and HAI Pump39:17 - Closing Thoughts --- Resources CHALLENGE Trial: Structured Exercise after Adjuvant Chemotherapy for Colon Cancerhttps://pubmed.ncbi.nlm.nih.gov/40450658/ ATOMIC Trial (Alliance A021502): Atezolizumab plus FOLFOX for Stage III Mismatch Repair Deficient Colon Cancerhttps://pubmed.ncbi.nlm.nih.gov/41880612/ Phase 2 LAVA-CRLM Trial: Microwave Ablation versus SBRT for Colorectal Liver Metastaseshttps://clinicaltrials.gov/study/NCT03654131 COLLISION Trial: Thermal Ablation versus Surgical Resection of Small-Size Colorectal Liver Metastaseshttps://pubmed.ncbi.nlm.nih.gov/39848272/ --- BackTable Tumor Board is the go-to multidisciplinary podcast for medical oncologists, surgical oncologists, and other healthcare professionals that play an active role in cancer care. Download the free BackTable app to get early access to new episodes, cases, and courses curated by physicians in your specialty. ► https://www.backtable.com/app

  ListenShow Notes
• 

  BackTable Tumor Board

  Ep. 81 CNS Disease in Breast Cancer: Clinical Management & Strategies with Dr. Barbara O'Brien

  Sep 15, 202647 min

  How should a breast cancer team manage central nervous system (CNS) disease now that systemic therapy, radiation, and surgery all compete for the first move? On this episode of BackTable Tumor Board, host Dr. Lindsay Peterson interviews Dr. Barbara O'Brien, neuro-oncologist at MD Anderson, about diagnosis, sequencing, and follow-up for CNS disease in breast cancer. They discuss risk by subtype, when to image and screen, and the importance of multidisciplinary workup for new brain metastases, as well as how to choose and sequence local and systemic options. --- Get the BackTable apphttps://www.backtable.com/app --- Timestamps 00:00 - Introduction04:24 - Risk by Subtype and CNS Screening Decisions07:42 - Multidisciplinary Evaluation of New Brain Metastases10:35 - Local Therapy Choices and Radiation Advances15:43 - HER-2 Positive Disease and CNS Active Therapy18:36 - Intrathecal Therapy, Response Imaging and CSF Testing23:34 - Triple Negative and HR+ Disease28:33 - Prognosis and Patient Counseling32:59 - Symptom Management and Supportive Care36:02 - Advice for Community Oncologists39:34 - Key Takeaways for Clinicians and Patients44:16 - Prevention of CNS Metastases46:46 - Closing Remarks --- More about this episode Dr. O'Brien reviews the shift away from whole brain radiation toward stereotactic radiosurgery, when to try CNS-active systemic therapy before radiation, and the role of proton craniospinal irradiation in leptomeningeal disease. The conversation covers HER2-positive disease, intrathecal trastuzumab, MRI and lumbar puncture for surveillance, and the evolving evidence for triple negative and hormone receptor positive disease. They close with strategies for symptom management, patient counseling, referral pathways for community oncologists, and why clinical trials and prevention are the future for patients with brain and leptomeningeal metastases. --- Resources HER2CLIMB, tucatinib with trastuzumab and capecitabine in pretreated HER2 positive metastatic breast cancerhttps://doi.org/10.1056/NEJMoa1914609 DESTINY-Breast12, trastuzumab deruxtecan in HER2 positive advanced breast cancer with or without brain metastaseshttps://doi.org/10.1038/s41591-024-03261-7 ASCO guideline update on management of advanced HER2 positive breast cancer and brain metastaseshttps://doi.org/10.1200/JCO.22.00520 American Society of Clinical Oncologyhttps://www.asco.org/ --- BackTable Tumor Board is the go-to multidisciplinary podcast for medical oncologists, surgical oncologists, and other healthcare professionals that play an active role in cancer care. Download the free BackTable app to get early access to new episodes, cases, and courses curated by physicians in your specialty. ► https://www.backtable.com/app

  ListenShow Notes
• 

  BackTable Tumor Board

  Ep. 80 Scaling Community CAR-T: Operational Lessons and Future Directions with Dr. Mike Byrne

  Sep 8, 202634 min

  How does delivering CAR-T in the community change patient care, and what has to happen next for these programs to scale? On this episode of the BackTable Tumor Board Podcast, host Aaron Lyss interviews Dr. Mike Byrne, hematologist at Tennessee Oncology and medical director for cellular therapy at OneOncology, about operational lessons and future directions for outpatient CAR-T therapy. They discuss the impact of faster time to treatment, building trust through local relationships, and the weekly pipeline management that keeps the program moving. --- Get the BackTable apphttps://www.backtable.com/app --- Timestamps 00:00 - Introduction02:21 - Patient Impact and Access to Therapy04:42 - Reducing Friction in the Referral Pathway07:50 - Expectations Versus Reality in Program Development10:35 - Managing the Weekly Patient Pipeline13:08 - Priorities for the Next Generation of CAR T16:14 - Iterating on CD19 Constructs and Manufacturing19:07 - Safety Profiles and Care Delivery Models23:54 - Cellular Therapy in Autoimmune Disease27:47 - Allogeneic and In Vivo CAR T32:09 - Wrap Up and Closing Remarks --- More about this episode Dr. Byrne describes two groups the program has reached: patients with rapidly progressing disease who could not withstand referral delays, and patients with low health literacy who followed treatment recommendations from their local oncologist. He describes operational changes that reduced vein-to-vein time to about a third of published figures and enabled the program to function independently of any single individual. The conversation then shifts to the future of cell therapy, covering innovations such as dual-targeting CD19 and CD20 constructs with a 4-1BB arm and shorter manufacturing times, the safety thresholds community oncology will use to select new products, early developments in autoimmune disease and the potential need for rheumatology partnerships, and whether allogeneic and in vivo CAR-T can reach patients in what Dr. Byrne calls cell therapy deserts. The episode closes by addressing ongoing challenges in access, evolving institutional partnerships, and the need for mature data as CAR-T therapy expands across new settings. --- Resources KITE-363 and KITE-753 in relapsed or refractory B-cell lymphoma, the dual targeting CD19 and CD20 CAR T program https://clinicaltrials.gov/study/NCT04989803 KITE-363 in refractory autoimmune disease, the autoimmune arm of the same constructhttps://clinicaltrials.gov/study/NCT07038447 iMMagine-1, pivotal study of anitocabtagene autoleucel, the BCMA CAR T with a December FDA decision date https://clinicaltrials.gov/study/NCT05396885 First in human data for in vivo CAR T in multiple myeloma, presented at the ASH annual meetinghttps://ascopost.com/issues/february-25-2026-supplement-ash-meeting-highlights-2025/early-findings-from-first-human-study-of-in-vivo-car-t-in-myeloma/ In vivo CAR T cell therapy, review of the 2025 ASH annual meeting updateshttps://pubmed.ncbi.nlm.nih.gov/41957634/ American Society of Hematology Annual Meetinghttps://www.hematology.org/meetings/annual-meetingMichael T. Byrne, DO, FACP, physician profile at Tennessee Oncologyhttps://tnoncology.com/physicians/michael-t-byrne-m-d/OneOncology appoints Dr. Michael Byrne as Medical Director for Cellular Therapyhttps://www.oneoncology.com/blog/oneoncology-appoints-dr-michael-byrne-as-medical-director-for-cellular-therapy/Aaron Lyss on the administrative demands of bringing CAR T into community practicehttps://www.ajmc.com/view/taking-the-giant-leap-into-car-t-managing-financial-and-administrative-challenges ---BackTable Tumor Board is the go-to multidisciplinary podcast for medical oncologists, surgical oncologists, and other healthcare professionals that play an active role in cancer care. Download the free BackTable app to get early access to new episodes, cases, and courses curated by physicians in your specialty. ► https://www.backtable.com/app

  ListenShow Notes
• 

  BackTable Tumor Board

  Ep. 79 Gynecologic Cancer Surveillance: Best Practices & Updates with Dr. Ritu Salani

  Sep 1, 202649 min

  Does catching cancer earlier with surveillance always translate to better outcomes for gynecologic cancer patients? On this episode of BackTable Women’s Health, hosts Dr. Mona Guo and Dr. Marcia Ciccone interview Dr. Ritu Salani, Professor of OBGYN at UCLA and lead author of the updated SGO surveillance clinical practice statements. They discuss how post–curative-intent surveillance has evolved amid limited prospective evidence, review the latest guidelines, and highlight the real-world challenges of balancing early detection, patient safety, and cost. --- Get the BackTable apphttps://www.backtable.com/app --- Timestamps 00:00 - Introduction03:05 - Evolving Guidelines and Consensus10:02 - Lead-Time Bias and Cost Considerations12:05 - Maintenance Therapy and Surveillance Nuances14:44 - Ovarian and Endometrial Cancer: Imaging vs Exam20:24 - Key Takeaways from the TOTEM Trial24:04 - Future Tools, Lifestyle Counseling, and Shared Care27:21 - Cytology, HPV Testing, and Post-Radiation Surveillance31:13 - Hormone Therapy Considerations34:37 - ctDNA and MRD Testing37:39 - Emerging Technologies and Limitations43:22 - Rapid Fire Takeaways45:33 - Closing Thoughts --- More about this episode The conversation explores practice variability, the lack of clear survival benefits from routine imaging and tumor markers, and the risks of cascade testing and lead-time bias. Dr. Salani reviews the TOTEM trial data for endometrial cancer, the importance of symptom review and pelvic exams (especially for lower genital tract cancers), and the reduced role of cytology, even in cervical cancer after radiation. They also discuss shared-care models, lifestyle counseling, hormone therapy considerations, and the promise and limitations of emerging technologies like ctDNA and MRD testing during maintenance therapy. --- Resources TOTEM Trialhttps://ascopubs.org/doi/abs/10.1200/jco.22.00471 2010 Ovarian Cancer CA-125 Trialhttps://pubmed.ncbi.nlm.nih.gov/20888993/ Society of Gynecologic Oncology Clinical Practice Statement on Surveillancehttps://pubmed.ncbi.nlm.nih.gov/41308226/ --- BackTable Tumor Board is the go-to multidisciplinary podcast for medical oncologists, surgical oncologists, and other healthcare professionals that play an active role in cancer care. Download the free BackTable app to get early access to new episodes, cases, and courses curated by physicians in your specialty. ► https://www.backtable.com/app

  ListenShow Notes

Recent guests on BackTable Tumor Board. Study who booked and why before you pitch.

Based on semantic analysis of episode topics and host coverage, this show is a strong guest fit for executives in:

Industry fit is computed by PitchCentric using vector embeddings of the show's episode catalog.